Excess positional mutual information predicts both local and allosteric mutations affecting beta lactamase drug resistance

MOTIVATION Bacterial resistance to antibiotics, particularly plasmid-encoded resistance to beta lactam drugs, poses an increasing threat to human health. Point mutations to beta-lactamase enzymes can greatly alter the level of resistance conferred, but predicting the effects of such mutations has been challenging due to the large combinatorial space involved and the subtle relationships of distant residues to catalytic function. Therefore we desire an information-theoretic metric to sensitively and robustly detect both local and distant residues that affect substrate conformation and catalytic activity. RESULTS Here, we report the use of positional mutual information in multiple microsecond-length molecular dynamics (MD) simulations to predict residues linked to catalytic activity of the CTX-M9 beta lactamase. We find that motions of the bound drug are relatively isolated from motions of the protein as a whole, which we interpret in the context of prior theories of catalysis. In order to robustly identify residues that are weakly coupled to drug motions but nonetheless affect catalysis, we utilize an excess mutual information metric. We predict 31 such residues for the cephalosporin antibiotic cefotaxime. Nine of these have previously been tested experimentally, and all decrease both enzyme rate constants and empirical drug resistance. We prospectively validate our method by testing eight high-scoring mutations and eight low-scoring controls in bacteria. Six of eight predicted mutations decrease cefotaxime resistance greater than 2-fold, while only one control shows such an effect. The ability to prospectively predict new variants affecting bacterial drug resistance is of great interest to clinical and epidemiological surveillance. AVAILABILITY AND IMPLEMENTATION Excess mutual information code is available at https://github.com/kassonlab/positionalmi CONTACT: kasson@virginia.edu.

[1]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[2]  G. Jacoby,et al.  Extended-spectrum beta-lactamases , 1989, Antimicrobial Agents and Chemotherapy.

[3]  F. Baquero,et al.  Dramatic Increase in Prevalence of Fecal Carriage of Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae during Nonoutbreak Situations in Spain , 2004, Journal of Clinical Microbiology.

[4]  Robert C. Edgar,et al.  MUSCLE: multiple sequence alignment with high accuracy and high throughput. , 2004, Nucleic acids research.

[5]  Jacqueline C. Hargis,et al.  Ligand-Induced Proton Transfer and Low-Barrier Hydrogen Bond Revealed by X-ray Crystallography. , 2015, Journal of the American Chemical Society.

[6]  S. Mobashery,et al.  The future of the β-lactams. , 2010, Current opinion in microbiology.

[7]  R. Bonnet,et al.  Novel Cefotaximase (CTX-M-16) with Increased Catalytic Efficiency Due to Substitution Asp-240→Gly , 2001, Antimicrobial Agents and Chemotherapy.

[8]  S. Levy,et al.  Antibacterial resistance worldwide: causes, challenges and responses , 2004, Nature Medicine.

[9]  B. Shoichet,et al.  The acylation mechanism of CTX-M beta-lactamase at 0.88 a resolution. , 2007, Journal of the American Chemical Society.

[10]  O. Abián,et al.  Distant and New Mutations in CTX-M-1 β-Lactamase Affect Cefotaxime Hydrolysis , 2011, Antimicrobial Agents and Chemotherapy.

[11]  M. Parrinello,et al.  Canonical sampling through velocity rescaling. , 2007, The Journal of chemical physics.

[12]  T. Wichelhaus,et al.  Integrated Detection of Extended-Spectrum-Beta-Lactam Resistance by DNA Microarray-Based Genotyping of TEM, SHV, and CTX-M Genes , 2009, Journal of Clinical Microbiology.

[13]  R. Bonnet,et al.  Prediction of the Evolution of Ceftazidime Resistance in Extended-Spectrum β-Lactamase CTX-M-9 , 2006, Antimicrobial Agents and Chemotherapy.

[14]  Richard Bonnet,et al.  Structure, function, and inhibition along the reaction coordinate of CTX-M beta-lactamases. , 2005, Journal of the American Chemical Society.

[15]  Yoshikazu Ishii,et al.  Acyl-intermediate Structures of the Extended-spectrum Class A β-Lactamase, Toho-1, in Complex with Cefotaxime, Cephalothin, and Benzylpenicillin* , 2002, The Journal of Biological Chemistry.

[16]  J. Cooper,et al.  The active site protonation states of perdeuterated Toho‐1 β‐lactamase determined by neutron diffraction support a role for Glu166 as the general base in acylation , 2011, FEBS letters.

[17]  M. Karplus,et al.  Molecular dynamics and protein function. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  N. Woodford,et al.  CTX-M: changing the face of ESBLs in Europe. , 2006, The Journal of antimicrobial chemotherapy.

[19]  D. M. Perry,et al.  Single-disk antibiotic-sensitivity testing of staphylococci; an analysis of technique and results. , 1959, A.M.A. archives of internal medicine.

[20]  H. Kamberaj,et al.  Extracting the causality of correlated motions from molecular dynamics simulations. , 2009, Biophysical journal.

[21]  Peter M. Kasson,et al.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..

[22]  W. Sougakoff,et al.  The TEM-3 β-lactamase, which hydrolyzes broad-spectrum cephalosporins, is derived from the TEM-2 penicillinase by two amino acid substitutions , 1988 .

[23]  P. Nordmann,et al.  Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum β-lactamase CTX-M-15 and of its structurally related β-lactamase CTX-M-3 , 2002 .

[24]  P. Nordmann,et al.  Biochemical analysis of the ceftazidime-hydrolysing extended-spectrum beta-lactamase CTX-M-15 and of its structurally related beta-lactamase CTX-M-3. , 2002, The Journal of antimicrobial chemotherapy.

[25]  Vijay S. Pande,et al.  A-Site Residues Move Independently from P-Site Residues in all-Atom Molecular Dynamics Simulations of the 70S Bacterial Ribosome , 2012, PloS one.

[26]  Benjamin R. Jack,et al.  Functional Sites Induce Long-Range Evolutionary Constraints in Enzymes , 2016, PLoS biology.

[27]  B. Shoichet,et al.  The Acylation Mechanism of CTX-M β-Lactamase at 0.88 Å Resolution , 2007 .

[28]  M. Karplus,et al.  Method for estimating the configurational entropy of macromolecules , 1981 .

[29]  Adrian J Mulholland,et al.  High level QM/MM modeling of the formation of the tetrahedral intermediate in the acylation of wild type and K73A mutant TEM-1 class A beta-lactamase. , 2009, The journal of physical chemistry. A.

[30]  J. Herrmann,et al.  Diversity of CTX-M beta-lactamases and their promoter regions from Enterobacteriaceae isolated in three Parisian hospitals. , 2002, FEMS microbiology letters.

[31]  Thomas M. Cover,et al.  Elements of Information Theory , 2005 .

[32]  Charles L Brooks,et al.  Correlated motion and the effect of distal mutations in dihydrofolate reductase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[33]  Sharon Hammes-Schiffer,et al.  Effect of mutation on enzyme motion in dihydrofolate reductase. , 2003, Journal of the American Chemical Society.

[34]  M. Gazouli,et al.  Sequence of the Gene Encoding a Plasmid-Mediated Cefotaxime-Hydrolyzing Class A β-Lactamase (CTX-M-4): Involvement of Serine 237 in Cephalosporin Hydrolysis , 1998, Antimicrobial Agents and Chemotherapy.

[35]  Effects of Ser130Gly and Asp240Lys Substitutions in Extended-Spectrum β-Lactamase CTX-M-9 , 2003, Antimicrobial Agents and Chemotherapy.

[36]  R. Bonnet,et al.  Effect of D240G substitution in a novel ESBL CTX-M-27. , 2003, The Journal of antimicrobial chemotherapy.

[37]  G. Bou,et al.  Structure-function studies of arginine at position 276 in CTX-M beta-lactamases. , 2008, The Journal of antimicrobial chemotherapy.

[38]  Arieh Warshel,et al.  Molecular dynamics simulations of biological reactions. , 2002, Accounts of chemical research.

[39]  R. Bonomo,et al.  Inhibition of class A beta-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. , 2008, Journal of the American Chemical Society.

[40]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[41]  R. Dror,et al.  Improved side-chain torsion potentials for the Amber ff99SB protein force field , 2010, Proteins.

[42]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[43]  Berk Hess,et al.  LINCS: A linear constraint solver for molecular simulations , 1997, J. Comput. Chem..

[44]  R. Cantón,et al.  The CTX-M β-lactamase pandemic , 2006 .

[45]  Oliver F. Lange,et al.  Generalized correlation for biomolecular dynamics , 2005, Proteins.

[46]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[47]  Hua Guo,et al.  Antibiotic deactivation by a dizinc beta-lactamase: mechanistic insights from QM/MM and DFT studies. , 2007, Journal of the American Chemical Society.

[48]  B. Shoichet,et al.  Structure and Dynamics of CTX-M Enzymes Reveal Insights into Substrate Accommodation by Extended-spectrum β-Lactamases , 2008 .

[49]  Vijay S Pande,et al.  Combining molecular dynamics with bayesian analysis to predict and evaluate ligand-binding mutations in influenza hemagglutinin. , 2009, Journal of the American Chemical Society.

[50]  J. Frère,et al.  Catalytic properties of class A beta-lactamases: efficiency and diversity. , 1998, The Biochemical journal.

[51]  A. Warshel Electrostatic Origin of the Catalytic Power of Enzymes and the Role of Preorganized Active Sites* , 1998, The Journal of Biological Chemistry.

[52]  M. Karplus,et al.  Collective motions in proteins: A covariance analysis of atomic fluctuations in molecular dynamics and normal mode simulations , 1991, Proteins.

[53]  R. Cantón,et al.  CTX-M Enzymes: Origin and Diffusion , 2012, Front. Microbio..